Advances in the study of S100A9 in cardiovascular diseases

Area of Science:

• Biochemistry
• Cardiology
• Immunology

Background:

• Cardiovascular diseases (CVD) present significant global health challenges, characterized by inflammation, oxidative stress, and fibrosis.
• S100A9, a calcium-binding protein secreted by myeloid cells, interacts with key receptors (TLR4, RAGE) and influences CVD-related pathological processes.
• Current research highlights S100A9's potential as a crucial biomarker for CVD diagnosis and prognosis.

Purpose of the Study:

• To review the latest advancements in the diagnostic, predictive, and therapeutic applications of S100A9 in inflammatory CVD.
• To elucidate the molecular mechanisms underlying S100A9's role in the progression of atherosclerosis, myocardial infarction, and arterial aneurysms.
• To identify novel predictive strategies and potential therapeutic targets for cardiovascular diseases.

Main Methods:

• Literature review of recent research on S100A9 and cardiovascular diseases.
• Analysis of S100A9's molecular interactions and signaling pathways in CVD pathogenesis.
• Synthesis of findings related to S100A9's biomarker potential and therapeutic implications.

Main Results:

• S100A9 is implicated in inflammatory responses, fibrosis, vascular calcification, and endothelial barrier dysfunction in CVD.
• S100A9 demonstrates significant potential as a diagnostic and predictive biomarker across various CVD types.
• The protein's molecular mechanisms offer insights into disease progression and potential intervention points.

Conclusions:

• S100A9 plays a critical role in the pathogenesis of inflammatory cardiovascular diseases.
• S100A9 serves as a promising biomarker for early detection and risk stratification of CVD.
• Targeting S100A9 pathways may offer novel therapeutic strategies for managing cardiovascular conditions.